ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - codeine phosphate 15.0 mg; paracetamol 325 mg - tablets - paracetamol, combinations excl. psycholeptics - relief of mild to moderate pain. relief of fever and cough associated with fever.

ישראל - עברית - Ministry of Health

a.bee-zee cons.& marketing ltd - lasalocid sodium 15 % - powder - medical additive for the prevention of coccidiosis in broilers and turkeys, cattle and sheep caused by various strains of eimeria.

ישראל - עברית - Ministry of Health

אהבה - מעבדות ים המלח בעמ - לחות לעור הפנים עם הגנה spf 15

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - lansoprazole - קפסולות - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long- term treatment and maintenance therapy for patients with gastro-oesophageal reflux disease (gerd) or duodenal ulcer. prevention of relapse in patients with gerd or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients ,with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short- term- treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - pioglitazone as hydrochloride - טבליה - pioglitazone as hydrochloride 15 mg - pioglitazone - pioglitazone - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.- pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients wi

ישראל - עברית - Ministry of Health

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 15 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

ישראל - עברית - Ministry of Health

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 15 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.